Adult Stem Cell Isolation from Synovial Fluid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a shortage of sufficient and accessible human stem cells capable of differentiating into various cell types, due to difficulties in isolation and procurement, particularly from adult tissues and embryos, which raises ethical and legal concerns, and requires alternative sources that do not rely on embryonic or fetal tissue.
Innovation Solution
The discovery of purified adult stem cells in synovial fluid and blood that are embryonic-like, capable of differentiating into ectoderm, mesoderm, and endoderm, and do not express certain surface markers, allowing for easy access and expansion without the need for feeder cells, providing a non-controversial source for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If stem cells are isolated from adult tissues such as bone marrow, then the cells can be obtained without ethical concerns, but the quantity and accessibility of such cells remain insufficient
Solution Approach 1:
The invention extracts stem cells from a previously unrecognized source (synovial fluid) rather than from traditional sources like bone marrow. This extraction from an unexpected location provides both ethical advantages and sufficient cell quantities, resolving the contradiction between ethical sourcing and cell availability.
Solution Approach 2:
The invention shifts the search dimension for stem cells from traditional adult tissues to synovial fluid, a previously unexplored source. This dimensional change in sourcing strategy simultaneously achieves ethical compliance and adequate cell supply.
2Quantity of substance
If stem cells are isolated from embryos or fetal tissue, then sufficient quantities can be obtained, but ethical and legal concerns arise
Solution Approach 1:
The invention extracts stem cells from synovial fluid, completely avoiding embryonic or fetal tissue sources. This extraction from an adult-derived fluid source eliminates ethical and legal concerns while providing sufficient cell quantities for therapeutic use.
3Object-affected harmful factors
If traditional isolation methods are used from bone marrow, then the process avoids ethical issues, but the isolation becomes technically difficult and costly
Solution Approach 1:
The invention extracts stem cells from synovial fluid, which is readily accessible through simple joint aspiration procedures. This extraction method is technically straightforward and cost-effective compared to bone marrow harvesting, while maintaining ethical advantages.
Solution Approach 2:
The synovial fluid naturally contains sufficient stem cells that can be harvested through minimally invasive procedures. The body's own synovial fluid serves as a self-renewing source, eliminating the need for complex isolation protocols required by bone marrow methods.
4Productivity
If feeder cells are used for stem cell expansion, then the cells can be cultured, but the process becomes more complex and requires additional components
Solution Approach 1:
The stem cells isolated from synovial fluid possess inherent self-renewal and self-differentiation capabilities that allow them to expand in culture without requiring feeder cells. This self-sufficient property simplifies the culture system while maintaining productive cell expansion.
Data Source
AI summary
The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided.